Influence of locoregional radiation treatment on tumor necrosis factor-α and interleukin-6 in the serum of patients with head and neck cancer

被引:25
作者
Akmansu, M
Unsal, D
Bora, H
Elbeg, S
机构
[1] Gazi Univ, Fac Med, Dept Radiat Oncol, TR-06510 Ankara, Turkey
[2] Gazi Univ, Fac Med, Dept Biochem, TR-06510 Ankara, Turkey
关键词
head and neck cancer; interleukin-6; radiotherapy; tumor necrosis factor-alpha;
D O I
10.1016/j.cyto.2005.02.009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Serum tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 levels in the serum of 34 patients with head and neck cancer (HNC) undergoing locoregional radiotherapy (RT) were examined. The aim of the RT was definitive in 19 and postoperative adjuvant in 15 patients. Serum TNF-alpha and IL-6 levels were recorded before RT and after the completion of the fifth week of RT. The mean TNF-alpha levels before and after RT were 28.26 +/- 2.87 and 83.03 +/- 7.47, and the mean IL-6 levels were 61.56 +/- 14.32 and 122.45 +/- 30.66, respectively. The statistical analysis yielded a significant rise in TNF-alpha levels with RT in all patients (p < 0.0001) and also in IL-6 levels in patients treated with postoperative adjuvant RT (p = 0.001). Irradiation is likely to cause an acute phase response, and the cytokines studied may be used to monitor this clinically important response in further trials. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:41 / 45
页数:5
相关论文
共 23 条
  • [1] Relationship between serum levels of interleukin-6, tumor necrosis factor-α and bone turnover markers in prostate cancer patients
    Akimoto, S
    Okumura, A
    Fuse, H
    [J]. ENDOCRINE JOURNAL, 1998, 45 (02) : 183 - 189
  • [2] Acute phase response during radiotherapy
    Cengiz, M
    Akbulut, S
    Atahan, IL
    Grigsby, PW
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 49 (04): : 1093 - 1096
  • [3] Chen Z, 1999, CLIN CANCER RES, V5, P1369
  • [4] Fayad L, 1998, LEUKEMIA LYMPHOMA, V65, P183
  • [5] Hallahan, 1996, Semin Radiat Oncol, V6, P250, DOI 10.1016/S1053-4296(96)80021-X
  • [6] HASKELL CM, 1995, CANC TREATMENT, P31
  • [7] Haveman J, 1998, ONCOL REP, V5, P679
  • [8] Hellman S, 2001, CANC PRINCIPLES PRAC, P265
  • [9] Herskind C, 1998, STRAHLENTHER ONKOL, V174, P12
  • [10] Ito H, 1999, SCAND J GASTROENTERO, V34, P1139